Literature DB >> 20581857

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.

Guo-hai Shi1, Ding-wei Ye, Xu-dong Yao, Shi-ling Zhang, Bo Dai, Hai-liang Zhang, Yi-jun Shen, Yao Zhu, Yi-ping Zhu, Wen-jun Xiao, Chun-guang Ma.   

Abstract

AIM: To investigate whether microRNA-21 was involved in mediating the chemoresistance of prostate cancer cells to docetaxel.
METHODS: A microarray technique was used to determine the miRNA profile in docetaxel-resistant PC3 cells. Real-time PCR was used to confirm the array results. miR-21 mimics and inhibitors were synthesized and introduced to cells using Lipofectamine 2000. Cell proliferation was examined with the CCK-8 assay. Luciferase reporter containing PDCD 3'UTR was constructed and the activity was detected by a dual luciferase assay. PDCD4 protein expression was evaluated using Western blot.
RESULTS: A docetaxel-resistant prostate cancer PC3 cell line (PC3R) was established . Using microarrays, miR-21 was found to be up-regulated in PC3R cells. Ectopic expression of miR-21 increased the resistance to docetaxel in PC3 wild type cells. In contrast, silencing of miR-21 in PC3R cells sensitized the cells to docetaxel. The IC(50) values for miR-21-silencing cells and control cells were 28.31 and 35.89 nmol/L, respectively. PDCD4, a direct target gene of miR-21, could mediate chemoresistance to docetaxel in PC3 cells.
CONCLUSION: Our findings suggest that miR-21 contributed to the resistance of PC3 cells to docetaxel, and that targeting miR-21 may offer a promising therapeutic approach in sensitizing prostate cancer to docetaxel treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20581857      PMCID: PMC4007720          DOI: 10.1038/aps.2010.48

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.

Authors:  Cristiana Lo Nigro; Monica Maffi; Jean Louis Fischel; Patricia Formento; Gerard Milano; Marco Merlano
Journal:  BJU Int       Date:  2008-05-20       Impact factor: 5.588

3.  Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma.

Authors:  H Zhang; I Ozaki; T Mizuta; H Hamajima; T Yasutake; Y Eguchi; H Ideguchi; K Yamamoto; S Matsuhashi
Journal:  Oncogene       Date:  2006-05-08       Impact factor: 9.867

4.  Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation.

Authors:  J L Cmarik; H Min; G Hegamyer; S Zhan; M Kulesz-Martin; H Yoshinaga; S Matsuhashi; N H Colburn
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

5.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.

Authors:  Aaron P Jansen; Corinne E Camalier; Nancy H Colburn
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells.

Authors:  R Chen; A B Alvero; D A Silasi; M G Kelly; S Fest; I Visintin; A Leiser; P E Schwartz; T Rutherford; G Mor
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

8.  MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths.

Authors:  Danish Sayed; Shweta Rane; Jacqueline Lypowy; Minzhen He; Ieng-Yi Chen; Himanshu Vashistha; Lin Yan; Ashwani Malhotra; Dorothy Vatner; Maha Abdellatif
Journal:  Mol Biol Cell       Date:  2008-05-28       Impact factor: 4.138

9.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

10.  Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.

Authors:  Olubunmi Afonja; Dominique Juste; Sharmistha Das; Sachiko Matsuhashi; Herbert H Samuels
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

View more
  61 in total

1.  miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN.

Authors:  Xiaomin Yu; Yulong Chen; Ruiyun Tian; Jianxia Li; Hongyan Li; Teng Lv; Qin Yao
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

Review 2.  Prostate cancer research in China.

Authors:  Shan-Cheng Ren; Rui Chen; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2013-04-22       Impact factor: 3.285

3.  Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.

Authors:  Qizhi Zheng; Sarah B Peskoe; Judit Ribas; Fatema Rafiqi; Tarana Kudrolli; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold
Journal:  Prostate       Date:  2014-09-22       Impact factor: 4.104

4.  Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.

Authors:  Frank Desarnaud; Peter Geck; Christopher Parkin; Gino Carpinito; Andrew N Makarovskiy
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

5.  MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Authors:  Cameron M Armstrong; Chengfei Liu; Wei Lou; Alan P Lombard; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2017-06       Impact factor: 4.104

6.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26

7.  Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Authors:  Emanuela Leone; Eugenio Morelli; Maria T Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 8.  Role of microRNAs in chemoresistance.

Authors:  Peter Magee; Lei Shi; Michela Garofalo
Journal:  Ann Transl Med       Date:  2015-12

9.  Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

Review 10.  MicroRNAs and drug resistance in prostate cancers.

Authors:  Feng Li; Ram I Mahato
Journal:  Mol Pharm       Date:  2014-04-29       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.